Prevalence, incidence, gender and age distribution, and economic burden of psoriasis worldwide and in Kazakhstan

Aidar Dairov 1 2 * , Assel Issabekova 1, Aliya Sekenova 1, Miras Shakhatbayev 1, Vyacheslav Ogay 1
More Detail
1 National Center for Biotechnology
2 L.N. Gumilyov Eurasian National University
* Corresponding Author
J CLIN MED KAZ, Volume 21, Issue 2, pp. 18-30.
OPEN ACCESS 188 Views 91 Downloads
Download Full Text (PDF)
Author Contributions: Conceptualization, A.D. and V.O.; methodology, A.D.; validation, A.D.; formal analysis, A.D. and A.I.; investigation, A.D.; resources, A.D.; data curation, A.D.; writing – original draft preparation, A.D.; writing – review and editing, A.D., A.S. and M.Sh.; visualization, A.D.; supervision, A.D.; project administration, A.D. and A.I.; funding acquisition, A.I. All authors have read and agreed to the published version of the manuscript.


Aim: This study aimed to conduct a literature review on the prevalence, incidence, gender and age distribution of psoriasis, as well as the economic burden of psoriasis worldwide, including Kazakhstan.
Material and methods: A literature review was conducted using keywords in PubMed, Scopus, Web of Science, databases, and Google Scholar to identify relevant articles.
Results: The prevalence of psoriasis varies by geographic location and race. However, psoriasis is predominantly common in Western countries and among people of European descent: in Norway (4.6%), France (4.42%), Portugal (4.4%), and the United States of America (3.0%). Significant differences in the prevalence of this disease were identified in Kazakhstan, ranging from 0.86% to 2.5%. In many Western countries, the incidence rate of psoriasis is significantly higher than the global incidence rate (57.8 cases per 100,000 population): in Denmark (199.5), Italy (230.62), and Israel (280), respectively. In Kazakhstan, the incidence rate is 35.0 per 100,000 population, which is almost 1.7 times lower than the global rate. Psoriasis affects both genders. There is a bimodal pattern of manifestation of psoriasis with early (type I) and late (type II) onset, which occurs in the age range of 30–40 years, and about 60 years. In addition, treating and providing medications to patients with psoriasis represents a significant economic burden for both the government and the patients themselves.
Conclusion: The study made it possible to determine the current epidemiological situation of psoriasis worldwide, including Kazakhstan, as well as to assess the economic burden of this disease.


Dairov A, Issabekova A, Sekenova A, Shakhatbayev M, Ogay V. Prevalence, incidence, gender and age distribution, and economic burden of psoriasis worldwide and in Kazakhstan. J CLIN MED KAZ. 2024;21(2):18-30.


  • Cheng L, Wang S, Peng C, Zou X, Yang C, Mei H, et al. Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study. Signal Trunsduct Target Ther. 2022;7:263.
  • Hepat A, Chakole S, Rannaware A. Psychological well-being of adult psoriasis patients: a narrative review. Cureus. 2023; 15(4):e37702.
  • National Psoriasis Foundation. Available at: Accessed December 21, 2023.
  • Alinaghi F, Calov M, Erik Kristensen L, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019; 80(1):251-265.e19.
  • Morrone A, Dell'Anna ML, Cristaudo A, Wubayehu T, Godefay H, Ab Barnabas G, et al. Psoriasis in Tigray, Ethiopia: Focusing on available treatments. Dermatol Ther. 2022; 35(3):e14718.
  • El-Komy MHM, Mashaly H, Sayed KS, Hafez V, El-Mesidy MS, Said ER, et al. Clinical and epidemiologic features of psoriasis patients in an Egyptian medical center. JAAD Int. 2020; 1(2):81-90.
  • Yahya H. Psoriasis in Kaduna, North-West Nigeria a twenty-year experience. Niger Postgrad Med J. 2022; 29(2):155-160.
  • Dickison P, Swain G, Peek JJ, Smith SD. Itching for answers: Prevalence and severity of pruritus in psoriasis. Australian J Dermatol. 2018; 59(3):206-209.
  • Kubanov AA, Bogdanova EV. Epidemiology of psoriasis in the Russian Federation according to the patient registry. Vestnik Dermatologii i Venerologii. 2022; 98(2):33-41.
  • Dogra S, Yadav S. Psoriasis in India: prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010; 76(6):595-601.
  • Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, Nakagawa H. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015; 5(1):e006450.
  • Ding X, Wang T, Shen Y, Wang X; Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012; 22(5), 663-667.
  • Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CEM, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017; 176(3):650-658.
  • Armstrong AW. Psoriasis. JAMA Dermatol. 2017; 153(9):956.
  • Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021; 21(3):170-173.
  • Iskandar IYK, Parisi R, Griffiths CEM, Ashcroft DM, Global Psoriasis Atlas. Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br J Dermatol. 2021; 184(2):243-258.
  • Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985; 13(3):450-456.
  • Chiang CC, Cheng WJ, Korinek M, Lin CY, Hwang TL. Neutrophils in psoriasis. Front Immunol. 2019; 10:2376.
  • Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015; 151(6):651-658.
  • Global Report on Psoriasis.  Geneva: World Health Organization, 2016. Available at:
  • Papp KA, Gniadecki R, Beecker J, Dutz J, Gooderham MJ, Hong CH, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther. 2021; 11(3):1053-1064.
  • AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis – comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020; 59(5):566-571.
  • Damiani G, Bragazzi NL, Aksut CK, Wu D, Alicandro G, McGonagle D, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021; 8:743180.
  • Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021; 157(8):940-946.
  • Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017; 31(2):205-212.
  • Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014; 70(3):512-516.
  • Petrella RJ, Gregory V, Luciani L, Barbeau M. Characteristics of chronic plaque psoriasis in Canada: a retrospective database study. Value Health. 2014; 17(3):PA284.
  • Romiti R, Amone M, Menter A, Milot HA. Prevalence of psoriasis in Brazil – a geographical survey. Int J Dermatol. 2017; 56(8):e167-e168.
  • Cherubin M, Tebar WR, Meneghini V, Bensenor IM. Psoriasis and associated risk factors: a cross-sectional analysis of the Brazilian Longitudinal Study of Adult Health. Rev Assoc Med Bras. 2023; 69(6):e20230038.
  • Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM, Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol.2013; 133(2):377-385.
  • Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010; 34(3):J314-J321.
  • Plunkett A, Marks R. A review of the epidemiology of psoriasis vulgaris in the community. Australian J Dermatol. 1998; 39(4):225-232.
  • Green AC. Australian aborigines and psoriasis. Australasian J Dermatol. 1984; 25(1):18-24.
  • Global Psoriasis Atlas. Available at: Accessed: December 13, 2023.
  • Kubanov AA, Bogdanova EV. Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010-2019 [in Russian]. Vest Dermatol Venerol. 2020; 96(5):7-18.
  • Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30‐year follow‐up of a population‐based cohort. British J Dermatol. 2013; 168(6):1303-1310.
  • Solberg SM. Psoriasis in Norway: a prescription-based registry study of incidence and prevalence. Acta Derm Venereol. 2023; 103:adv4591.
  • Egeberg A, Skov L, Gislason GH, Thyssen JP, Mallbris L. Incidence and prevalence of psoriasis in Denmark. Acta Derm Venereol. 2017; 97(7):808-812.
  • Radtke MA, Schäfer I, Glaeske G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol.2017; 31(1):151-157.
  • Augustin M, Radtke MA, Glaeske G, Reich K, Christophers E, Schaefer I, Jacobi A. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015; 231(1):35-40.
  • Richard MA, Sei JF, Philippe C, Taieb C, Joly P, Ezzedine K. Prevalence of comorbidities in atopic dermatitis and psoriasis in the French population. Ann Dermatol Venereol. 2021; 148(1):28-33.
  • Ferrándiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr. 2014; 105(5):504-509.
  • Puig L, Ruiz de Morales JG, Dauden E, Andreu JL, Cervera R, Adán A, et al. Prevalence of ten immune-mediated inflammatory diseases (IMID) in Spain [in Spanish]. Rev Esp Salud Publica. 2019; 93:e201903013. Available at:
  • Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Solé M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, et al. Epidemiology of psoriasis. A population-based study [in Spanish]. Actas Dermosifiliogr. 2019; 110(5):385-392.
  • Torres T, Filipe P, Brandão FM, Figueiredo A, Soares AP, Basto AS, et al. Epidemiology of psoriasis in Portugal: a population-based study. Acta Med Port. 2023; 36(9):541-549.
  • Gianfredi V, Casu G, Bricchi L, Kacerik E, Rongioletti F, Signorelli C. Epidemiology of psoriasis in Italy: burden, cost, comorbidities and patients’ satisfaction. A systematic review. Acta Biomed. 2022; 93(6):e2022332.
  • Nicolescu AC, Bucur S, Giurcăneanu C, Gheucă-Solovăstru L, Constantin T, Furtunescu F, et al. Prevalence and characteristics of psoriasis in Romania – first study in overall population. J Pers Med. 2021; 11(6):523.
  • Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009; 89(3):262-266.
  • Tsai TF, Wang TS, Hung ST, Ching Tsai PI, Schenkel B, Zhang M, Tang CH. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011; 63(1):40-46.
  • Iskandar IYK, Chen TC, Chen LC, Lee MS, Yang YY, Wang TC, et al. Incidence, prevalence, and mortality of people with psoriasis and psoriatic arthritis in Taiwan: a nationwide cohort study. Acta Derm Venereol. 2022; 102:adv00807.
  • Han JH, Lee JH, Han KD, Seo HM, Bang CH, Park YM, et al. Epidemiology and medication trends in patients with psoriasis: a nationwide population-based cohort study from Korea. Acta Derm Venereol. 2018; 98(4):396-400.
  • Goto H, Nakatani E, Yagi H, Moriki M, Sano Y, Miyachi Y. Late-onset development of psoriasis in Japan: a population-based cohort study. JAAD Int. 2021; 2:51-61.
  • Choon SE, Wright AK, Griffiths CEM, Tey KE, Wong KW, Lee YW, et al. Incidence and prevalence of psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in the Teleprimary Care (TPC®) clinical information system from 2010 to 2020. Br J Dermatol. 2022; 187(5):713-721.
  • Schonmann Y, Ashcroft DM, Iskandar IYK, Parisi R, Sde-Or S, Comaneshter D, et al. Incidence and prevalence of psoriasis in Israel between 2011 and 2017. J Eur Acad Dermatol Venereol. 2019; 33(11):2075-2081.
  • Shreberk-Hassidim R, Galili E, Hassidim A, Ramot Y, Merdler I, Baum S, et al. Epidemiology and comorbidities of psoriasis among Israeli adolescents: a large cross-sectional study. Dermatology. 2019; 235(6):488-494.
  • Sewerin P, Brinks R, Schneider, M, Haase I, Vordenbäumen S. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann Rheum Dis.2019; 78(2):286-287.
  • Olisova O.Ju. Kozhnye i venericheskie bolezni: uchebnik [in Russian]. Moscow: Prakticheskaja medicina; 2015. 288 p. Available at:
  • Global Psoriasis Atlas. Annual Report. April 2022 – March 2023. 14-15. Available at:
  • Imafuku S, Zheng M, Tada Y, Zhang X, Theng C, Thevarajah S, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018; 45(7):805-811.
  • Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007; 25(6):535-546.
  • Zheng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017; 44(8):863-872.
  • Wei J.C.C, Shi LH, Huang JY, Wu XF, Wu R, Chiou JY. Epidemiology and medication pattern change of psoriatic diseases in Taiwan from 2000 to 2013: nationwide, population-based cohort study. J Rheumatol. 2018; 45(3):385-392.
  • Dzhetpisbaeva ZS. Lechenie psoriaza u bol'nyh pozhilogo i starcheskogo vozrasta s ispol'zovaniem deproteinizirovannogo gemodializata (Aktovegina) (Treatment of psoriasis in elderly and senile patients using deproteinized hemodialysate (Actovegin) [in Russian]. Dis cand med sci. Almaty, 2001. 100 p.
  • Esengaraeva ZB, Tashenova ZhM. Sluchaj iz praktiki 3-h klinicheskih form psoriaza (A case study of 3 clinical forms of psoriasis) [in Russian]. Vestnik AGIUV.2011; 1:56-57. Available at:
  • Shortanbaeva ZhA, Almenova LT, Beisebaeva UT, Khabizhanov AB, Abilkhayir AS, Babazade NB, Khalmirzayeva UP. Psoriatic disease: etiology, pathogenesis, current stage [in Russian]. Vestnik KazNMU. 2017; 4:484-486. Available at:
  • Alikbaev TZ, Raznatovskiy KI, Vasilyeva NV, Avdeeva MV, Filatov VN. The state of morbidity and the provision of specialized medical care for patients with psoriasis [in Russian]. Health Care of the Russian Federation. 2019; 63(2):73-78. Available at:
  • Gudinova ZhV, Okhlopkov VA, Poleshchuk EI, Zhernakova GN. Incidence of psoriasis depending on the region of the Russian Federation [in Russian]. Rus J Skin Vener Dis. 2018; 21(2):85-89.
  • WHO. Report of the secretariat to the 67-th session of the World Health Assembly. A67/18. March 21, 2014. Psoriasis. [in Russian]. Available at:
  • Burshtein J, Strunk A, Garg A. Incidence of psoriasis among adults in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2021; 84(4):102-1029.
  • Lecaros C, Dunstan J, Villena F, Ashcroft DM, Parisi R, Griffiths CEM, et al. The incidence of psoriasis in Chile: an analysis of the National Waiting List Repository. Clin Exp Derm. 2021; 46(7):1262-1269.
  • Kungurov NV, Kohan MM, Syrneva TA, Shakirova AN, Kuznetsov ID. Features and trends of the incidence and prevalence of psoriasis in the subjects of the Russian Federation for the period 2009-2017. Int J Applied Fundamental Res. 2021; 8:9-15. Available at:
  • Kojanov AS, Usubaliev MB. The spread of psoriasis in the Kyrgyz Republic [in Russian]. Int J App Fund Res. Med Sci. 2015; 12:264-268. Available at:
  • Kazakh Scientific Center of Dermatology and Infectious Diseases. Available at: Accessed: January 25, 2024.
  • Orazymbetova DA. Regional'nye osobennosti kliniki i techenija psoriaza v Respublike Kazahstan (Regional features of the clinic and course of psoriasis in the Republic of Kazakhstan) [in Russian]. Dis doct med sci. Almaty, 2000. 186 p. Available at:
  • Rysbekova DE, Beissebayeva UT, Mashkunova OV. Quality of life in comorbid conditions in patients with psoriasis [in Russian]. Vestnik KazNMU. 2019; 4:44-49.Available at:
  • Abishev AT. Analiz sostojanija dermatovenerologicheskoj sluzhby Respubliki Kazahstan po itogam 2020 goda (Analysis of the state of the dermatovenerological service of the Republic of Kazakhstan based on the results of 2020) [in Russian]. Voprosy dermatologii i venerologii. 2021; 1-2:21-29. Available at:
  • Abishev AT. Dinamika zabolevaemosti boleznjami kozhi i podkozhnoj kletchatki v Respublike Kazahstan v period s 2014-2020 gg (Dynamics of the incidence of diseases of the skin and subcutaneous tissue in the Republic of Kazakhstan in the period from 2014-2020) [in Russian]. Voprosy dermatologii i venerologii. 2021; 1-2:29-37. Available at:
  • Abishev AT, Dzhusupgalieva MH, Tonkonogova NV, Kasenova OV, Kabazieva GSh. Struktura dermatologicheskoj zabolevaemosti v Respublike Kazahstan (Structure of dermatological morbidity in the Republic of Kazakhstan) [in Russian]. Sankt-Peterburgskie dermatologicheskie chtenija. Materialy XVII Nauchno-prakticheskoj konferencii dermatovenerologov i kosmetologov s mezhdunarodnym uchastiem, October 26-27, 2023, St. Petersburg. P. 11-12. Available at:
  • Taubaeva AA. Osnovnye pokazateli raboty kliniki KNCDIZ za 8 mesjacev 2021 goda (Key performance indicators of the KSCDID clinic for 8 months of 2021) [in Russian]. Voprosy dermatologii i venerologii. 2021; 3-4:48-50. Available at:
  • Igissinov N, Kulmirzayeva D, Bilyalova Z, Akpolatova G, Mamyrbayeva M, Zhumagaliyeva G. Age and spatial peculiarities of non-neoplastic diseases of the skin and subcutaneous tissue in Kazakhstan, 2003-2015. Iran J Public Health. 2017; 46(11):1575-1578.
  • Nurkhasimova RG, Aldabergenova SHA, Kuvandikov MK, Mirzakhmedov EA. Chastota i rasprostranennost psoriaza u zhitelej, prozhivayushchikh v ekologicheski neblagopriyatnom regione Respubliki Kazakhstan (Frequency and prevalence of psoriasis in residents living in an environmentally unfavorable region of the Republic of Kazakhstan) [in Russian]. Dostizheniya sovremennoj nauki: materialy Mezhdunarodnoj nauchno-prakticheskoj konferentsii, September 20-21, 2017, Kursk. P. 136-139.
  • Pacienty s psoriazom v Kazahstane stali poluchat' jeffektivnuju genno-inzhenernuju terapiju (Patients with psoriasis in Kazakhstan began to receive effective genetic engineering therapy) [in Russian]. Available at: Accessed: December 12, 2023.
  • Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, on behalf of the Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369:m1590.
  • Guillet C, Seeli C, Nina M, Maul LV, Maul JT. The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis. Int J Womens Dermatol. 2022; 8(2):e010.
  • Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583):263-271.
  • Bayev AI, Dorofeeva IS, Ashuyeva ZI. Experience in application of methodrexat in the treatment of medium-heavy forms of psoriasis. Meditsina (Almaty). 2018; 11(197):78-82 [in Russian]. 10.31082/1728-452X-2018-197-11-78-82.
  • Maul JT, Fröhlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, et al. Access to psoriasis treatment in Brazil and Chile: a cross-sectional multicentre Global Healthcare Study on Psoriasis. Br J Dermatol. 2023; 188(4):533-541.
  • Kaurova TV. K probleme social'noj adaptacii pri kozhnyh zabolevanijah: vzgljad sovremennoj molodezhi (To the problem of social adaptation in skin diseases: the view of modern youth) [in Russian]. Sankt-Peterburgskie dermatologicheskie chtenija. Materialy XVII Nauchno-prakticheskoj konferencii dermatovenerologov i kosmetologov s mezhdunarodnym uchastiem, October 26-27, 2023, St. Petersburg. P. 40-41. Available at:
  • Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: A study on the morbidity and financial effects of having psoriasis in Australia. Australian J Dermatol. 2002; 43(4):255-261.
  • Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006; 4:35.
  • Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis. Indian Dermatol Online J. 2016; 7(6):481-488.
  • Gupta A, Bhalani S, Chopra A, Jabin F, Gaur A, Kukreja I, et al. Epidemiological disease burden and cost of illness of psoriasis in the US. Value Health. 2022; 25(7):S460-S461.
  • Godovoj otchet o dejatel'nosti NAO «Fond social'nogo medicinskogo strahovanija» za 2021 god (Annual report on the activities of the NJSC «Social Health Insurance Fund» for 2021) [in Russian]. Available at:
  • Nacional'nyj doklad po razvitiju pervichnoj mediko-sanitarnoj pomoshhi v Respublike Kazahstan, 2023 (National report on the development of primary health care in the Republic of Kazakhstan, 2023) [in Russian]. Almaty: KazNMU, 2023. – 108 p. Available at:
  • Danielsen K, Duvetorp A, Iversen L, Østergaard M, Seifert O, Tveit KS, Skov L. Prevalence of psoriasis and psoriatic arthritis and patient perceptions of severity in Sweden, Norway and Denmark: results from the Nordic patient survey of psoriasis and psoriatic arthritis. Acta Derm Venereol. 2019; 99(1):18-25.
  • Zheng X, Wang Q, Luo Y, Lu W, Jin L, Chen M, et al. Seasonal variation of psoriasis and its impact in the therapeutic management: a retrospective study on Chinese patients. Clin Cosmet Investig Dermatol. 2021, 14:459-465.